• Active against MDR pathogens, such as ESBL-Producing E. coli and K. pneumoniae.
• 88% efficacy rate in IAI in systematic review and meta-analysis.
• 94% microbiological cure rate in cUTI

Effective in
Urinary Tract Infections

• Intra-abdominal infections
• Bone & Joint Infections
• Skin and Soft tissue infections

Adult Dose: 50 – 80mg /kg/day/ in 2 – 4 divided dosage LV. or LM. for 07 to 14 days.